Literature DB >> 11929839

Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy.

George N Naumov1, Ian C MacDonald, Pascal M Weinmeister, Nancy Kerkvliet, Kishore V Nadkarni, Sylvia M Wilson, Vincent L Morris, Alan C Groom, Ann F Chambers.   

Abstract

Tumors can recur years after treatment, and breast cancer is especially noted for long periods of dormancy. The status of the cancer during this period is poorly understood. As a model to study mechanisms of dormancy, we used murine D2.0R mammary carcinoma cells, which are poorly metastatic but form occasional metastases in liver and other organs after long latency. Highly metastatic D2A1 cells provided a positive, metastatic control. Our goals were to learn how the cell lines differ in survival kinetics in a secondary site and to seek evidence for the source of D2.0R dormancy. In spontaneous metastasis assays from mammary fat pad injections, we found evidence for dormancy because of a persistence of large numbers of solitary cells in the liver. To quantify the fate of cells after arrival in liver, experimental metastasis assays were used. To permit identification of cells that had not divided, cells were labeled before injection with fluorescent nanospheres, which were diluted to undetectable levels by cell division. Cancer cells were injected i.v. to target them to the liver and coinjected with reference microspheres to monitor cell survival. Dormancy was defined as retention of nanosphere fluorescence in vivo, as well as negative staining for the proliferation marker Ki67. A large proportion of D2.0R cells persisted as solitary dormant cells. No metastases formed, but viable cells could be recovered from the liver 11 weeks after injection. Large numbers of solitary, dormant, Ki67-negative D2A1 cells were also detected against a background of progressively growing metastases. Thus, this study identified a possible contributor to tumor dormancy: solitary, dormant cells that persist in tissue. If such cells are present in patients, they could contribute to tumor recurrence and would not be susceptible to current therapeutic strategies targeting proliferating cells.

Entities:  

Mesh:

Year:  2002        PMID: 11929839

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  122 in total

Review 1.  The connectivity of lymphogenous and hematogenous tumor cell dissemination: biological insights and clinical implications.

Authors:  Jonathan P Sleeman; Blake Cady; Klaus Pantel
Journal:  Clin Exp Metastasis       Date:  2012-06-06       Impact factor: 5.150

Review 2.  Tumor cell dormancy induced by p38SAPK and ER-stress signaling: an adaptive advantage for metastatic cells?

Authors:  Aparna C Ranganathan; Alejandro P Adam; Lin Zhang; Julio A Aguirre-Ghiso
Journal:  Cancer Biol Ther       Date:  2006-07-01       Impact factor: 4.742

3.  Combined SFK/MEK inhibition prevents metastatic outgrowth of dormant tumor cells.

Authors:  Lara H El Touny; Anthony Vieira; Arnulfo Mendoza; Chand Khanna; Mark J Hoenerhoff; Jeffrey E Green
Journal:  J Clin Invest       Date:  2013-12-09       Impact factor: 14.808

Review 4.  Does tumour dormancy offer a therapeutic target?

Authors:  Paul E Goss; Ann F Chambers
Journal:  Nat Rev Cancer       Date:  2010-11-04       Impact factor: 60.716

5.  Metastatic dissemination patterns of different primary tumors to the spine and other bones.

Authors:  Julia S Onken; Lucius S Fekonja; Romy Wehowsky; Vanessa Hubertus; Peter Vajkoczy
Journal:  Clin Exp Metastasis       Date:  2019-08-16       Impact factor: 5.150

Review 6.  Microenvironmental regulation of tumor progression and metastasis.

Authors:  Daniela F Quail; Johanna A Joyce
Journal:  Nat Med       Date:  2013-11       Impact factor: 53.440

Review 7.  Mechanisms governing metastatic dormancy and reactivation.

Authors:  Filippo G Giancotti
Journal:  Cell       Date:  2013-11-07       Impact factor: 41.582

Review 8.  In vivo animal models for studying brain metastasis: value and limitations.

Authors:  Inderjit Daphu; Terje Sundstrøm; Sindre Horn; Peter C Huszthy; Simone P Niclou; Per Ø Sakariassen; Heike Immervoll; Hrvoje Miletic; Rolf Bjerkvig; Frits Thorsen
Journal:  Clin Exp Metastasis       Date:  2013-01-16       Impact factor: 5.150

9.  Modeling boundary conditions for balanced proliferation in metastatic latency.

Authors:  Donald P Taylor; Jakob Z Wells; Andrej Savol; Chakra Chennubhotla; Alan Wells
Journal:  Clin Cancer Res       Date:  2013-01-17       Impact factor: 12.531

Review 10.  Basic and translational advances in cancer metastasis: Nm23.

Authors:  Taoufik Ouatas; Massimiliano Salerno; Diane Palmieri; Patricia S Steeg
Journal:  J Bioenerg Biomembr       Date:  2003-02       Impact factor: 2.945

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.